TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31362882

Group type: EXPERIMENTAL
Intervention: Nebulized Ketamine 1mg.kg‐1 (Group K‐N1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nebulized Ketamine 2mg.kg‐1 (Group K‐N2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine 0.5mg.kg‐1 (Group K‐IV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline Placebo (Group C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous and Nebulized Ketamine Groups
Number of subjects: 100
Study: 28062595

Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET/CT at 3 h after injection
Number of subjects: 112

Group type: COMPARATOR
Intervention: 68Ga-PSMA-11 PET/CT at 1 h after injection
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg) before late scans
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Late scans (3 h after injection)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Early scans (1 h after injection)
Number of subjects: 112
Study: 26016656

Group type: EXPERIMENTAL
Intervention: Polysomnographic (PSG) recordings on Day 21 (D21) and Day 51 (D51) of the 70-day patrol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Subjective assessments of sleep, sleepiness, mood, and anxiety on D21 and D51
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Urine cortisol levels taken after sleep
Number of subjects: 19
Study: 23896980

Group type: EXPERIMENTAL
Intervention: Sirukumab 1 mg/kg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sirukumab 4 mg/kg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sirukumab 10 mg/kg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sirukumab (all doses)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 22321594

Group type: EXPERIMENTAL
Intervention: Vaccine group (n=81)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (n=75)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Vaccine group (n=25)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Overall (n=194)
Number of subjects: 261
Study: 18927241

Group type: EXPERIMENTAL
Intervention: Vernakalant hydrochloride injection (3 mg/kg initially via 10-minute intravenous infusion followed by a second 2 mg/kg 10-minute infusion if atrial fibrillation persisted)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Vernakalant hydrochloride injection (1 or 2 infusions)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Vernakalant hydrochloride injection
Number of subjects: 4
Study: 17335300

Group type: EXPERIMENTAL
Intervention: Rupatadine
Number of subjects: 0
Study: 15033130

Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 11206684

Group type: EXPERIMENTAL
Intervention: Sildenafil (5 to 200 mg)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1218
Study: 9795316

Group type: EXPERIMENTAL
Intervention: ACLS medications (epinephrine, atropine, bicarbonate, calcium, lidocaine)
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Bicarbonate
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 773
Study: 7649749

Group type: EXPERIMENTAL
Intervention: Inpatient care for decedents
Number of subjects: 914

Group type: COMPARATOR
Intervention: Inpatient care for nondecedents
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Nonwhite patients
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Inpatient nights and costs
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 914
Study: 2745500

Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 0
Study: 237234

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 51

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-randomized medical group
Number of subjects: 51
Study: 30759221

Group type: EXPERIMENTAL
Intervention: Subcutaneous denosumab 60 mg every 6 months for 3 years, then 7 years of open-label denosumab
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Subcutaneous denosumab 60 mg
Number of subjects: 45
Study: 28392436

Group type: EXPERIMENTAL
Intervention: PRX-106 (2mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PRX-106 (8mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PRX-106 (16mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PRX-106 (all doses)
Number of subjects: 14
Study: 24902868

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 34
Study: 23263473

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (3.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (5.25 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21109557

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 25 mg subcutaneous injections twice weekly
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 19755091

Group type: EXPERIMENTAL
Intervention: Sevoflurane 2%
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Isoflurane 1.2%
Number of subjects: 53
Study: 17306906

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VC)
Number of subjects: 94
Study: 14984382

Group type: EXPERIMENTAL
Intervention: Omeprazole, metronidazole and clarithromycin (OMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole and placebo antimicrobials (OPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: OMC vs. OPP
Number of subjects: 0
Study: 11300383

Group type: EXPERIMENTAL
Intervention: Etomidate (ETO group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thiopental (THIO group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 10492661

Group type: EXPERIMENTAL
Intervention: Itraconazole pulse therapy (1 week 400 mg daily, 3 months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continuous terbinafine dosing (250 mg daily, 3 months)
Number of subjects: 51
Study: 1725023

Group type: EXPERIMENTAL
Intervention: Ramipril (5 or 10 mg daily)
Number of subjects: 502
Study: 6523394

Group type: EXPERIMENTAL
Intervention: Artificial synovial fluid (ASF) and its complexes (PVP-hyaluronate, PVP, cyclophosphamide, hydrocortisone, arteparone)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Kenalog or placebo
Number of subjects: 520
Study: 30908754

Group type: EXPERIMENTAL
Intervention: Intrapericardial (IP) Tranexamic Acid
Number of subjects: 97

Group type: COMPARATOR
Intervention: Intravenous (IV) Tranexamic Acid
Number of subjects: 97
Study: 29575637

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study: 28089473

Group type: EXPERIMENTAL
Intervention: Box trainer
Number of subjects: 36

Group type: COMPARATOR
Intervention: VR trainer
Number of subjects: 36
Study: 23652351

Group type: EXPERIMENTAL
Intervention: HFD plus adenoviral vectors encoding Mfn2
Number of subjects: 4

Group type: COMPARATOR
Intervention: HFD
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: HFD plus adenoviral vectors
Number of subjects: 4

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 4
Study: 21365230

Group type: EXPERIMENTAL
Intervention: Pediatric ESSQ certification process
Number of subjects: 29
Study: 20031692

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 1983

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1983
Study: 17942472

Group type: EXPERIMENTAL
Intervention: Data handling capacity establishment and monitoring through national and international collaboration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data collection and fieldwork supervision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community advisory board involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kappa statistics for inter- and intra-observer agreement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technical Errors of Measurement for anthropometric measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audit trail analysis for error correction rates
Number of subjects: 0
Study: 15110728

Group type: EXPERIMENTAL
Intervention: Human body stimuli (silhouettes and stick figures)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimuli (object silhouettes, object stick figures, scrambled silhouettes of bodies, body parts, and objects)
Number of subjects: 0
Study: 11567807

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (120 cGy b.i.d.)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Accelerated-hyperfractionated radiotherapy (160 cGy b.i.d.)
Number of subjects: 81
Study: 10326743

Group type: EXPERIMENTAL
Intervention: Pidotimod (400 mg oral bottle/day for 90 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 26
Study: 7927099

Group type: EXPERIMENTAL
Intervention: Flupirtine (100 mg, n = 35)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Tramadol (50 mg, n = 36)
Number of subjects: 71
Study: 2685177

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass operation
Number of subjects: 838

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 838
Study: 131310

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (solvent only)
Number of subjects: 0
Study: 31823345

Group type: EXPERIMENTAL
Intervention: ANCOVA with unequal randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robust sandwich variance estimators
Number of subjects: 0
Study: 29473975

Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF + RBV for 8 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF for 12 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF + RBV for 12 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF without RBV for 12 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF for 16 weeks
Number of subjects: 82
Study: 28716117

Group type: EXPERIMENTAL
Intervention: Stress Prevention@Work intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (waiting list design)
Number of subjects: 0
Study: 25459098

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR) - 15 mcg ethinyl estradiol/150 mcg etonogestrel
Number of subjects: 132

Group type: COMPARATOR
Intervention: Combined oral contraceptive (COC) - 20 mcg ethinyl estradiol/100 mcg levonorgestrel
Number of subjects: 132
Study: 24039738

Group type: EXPERIMENTAL
Intervention: bisoprolol (5 mg)
Number of subjects: 109

Group type: COMPARATOR
Intervention: atenolol (50 mg)
Number of subjects: 109
Study: 21463508

Group type: EXPERIMENTAL
Intervention: SODIS promotion campaign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SODIS promotional events participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Household characteristics (women included)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Household characteristics (latrine ownership)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Household characteristics (presence of severely wasted children)
Number of subjects: 0
Study: 18071814

Group type: EXPERIMENTAL
Intervention: Filtered signal-averaged P-wave duration measurement during pneumoperitoneum (PP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard ECG measurement
Number of subjects: 20
Study: 16492206

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30-45 mg/day
Number of subjects: 283

Group type: COMPARATOR
Intervention: Gliclazide 80-320 mg/day
Number of subjects: 283
Study: 12944338

Group type: EXPERIMENTAL
Intervention: Enrichment program (ages 3-5 years)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual community conditions (control group)
Number of subjects: 83
Study: 11098021

Group type: EXPERIMENTAL
Intervention: GnRH analogues (6 months down-regulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Laparoscopic laser diathermy
Number of subjects: 18
Study: 9330023

Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: fluvoxamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 8355859

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg tid
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg tid
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg tid
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 2980323

Group type: EXPERIMENTAL
Intervention: Iopentol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium iothalamate (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iohexol (Control)
Number of subjects: 0
Study: 31568094

Group type: EXPERIMENTAL
Intervention: Robot-assisted screw insertion
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conventional fluoroscopy-assisted screw insertion
Number of subjects: 135
Study: 29627257

Group type: EXPERIMENTAL
Intervention: Robotic-arm-assisted UKA
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional UKA
Number of subjects: 139
Study: 25503711

Group type: EXPERIMENTAL
Intervention: Swim training with inspiratory muscle training (N=8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Swim training only (N=8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Swim training with sham‐inspiratory muscle training (N=8)
Number of subjects: 24
Study: 25681312

Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 1434
Study: 23053685

Group type: EXPERIMENTAL
Intervention: Scapular-focused treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 22
Study: 22166673

Group type: EXPERIMENTAL
Intervention: No sedation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sedation with daily interruption
Number of subjects: 140
Study: 19092340

Group type: COMPARATOR
Intervention: TAC-PL (Tacrolimus - Placebo)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: TAC-ST (Tacrolimus - Short-term Steroid)
Number of subjects: 156
Study: 16441532

Group type: EXPERIMENTAL
Intervention: Consultation with a rheumatology clinical nurse specialist
Number of subjects: 71

Group type: COMPARATOR
Intervention: Outpatient staff nurse for safety monitoring only
Number of subjects: 71
Study: 12900683

Group type: EXPERIMENTAL
Intervention: L-arginine + CHO (10 g L-arginine with 70 g carbohydrate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (glycine + CHO)
Number of subjects: 0
Study: 10879440

Group type: EXPERIMENTAL
Intervention: Resistance training (BR-Tr)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-training control (BR-Cont)
Number of subjects: 9
Study: 9109106

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: m-CPP administration
Number of subjects: 17
Study: 8211009

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 4017679

Group type: EXPERIMENTAL
Intervention: Enriched oxygen for either six hours or 20 minutes prior to testing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Room air for either six hours or 20 minutes prior to testing
Number of subjects: 10
Study: 29490012

Group type: EXPERIMENTAL
Intervention: Structured, moderate-intensity physical activity (PA) program consisting of center-based (twice/week) and home-based (three to four times per week) aerobic, resistance, and flexibility training
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education (HE) program combined with upper extremity stretching
Number of subjects: 1635
Study: 26858193

Group type: EXPERIMENTAL
Intervention: Everolimus initiated at 4.5 mg/m2/day, titrated to blood trough levels of 5-15 ng/mL.
Number of subjects: 18
Study: 24853308

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Control (no IPT)
Number of subjects: 2500
Study: 24453831

Group type: EXPERIMENTAL
Intervention: Double dose (DD) of aspirin and clopidogrel (n = 58)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard dose (SD) of aspirin and clopidogrel (n = 58)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Double dose (DD) of aspirin and clopidogrel
Number of subjects: 116
Study: 21112451

Group type: EXPERIMENTAL
Intervention: High-Intensity Intervention (HII; 30-min motivational interview plus seven routine telephone calls after hospital discharge)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Low-Intensity Intervention (LII; 15-min counseling about the benefits of quitting)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 237
Study: 18256968

Group type: EXPERIMENTAL
Intervention: Psychotherapy methods (brief interventions and cognitive-behavioral therapy)
Number of subjects: 400000

Group type: EXPERIMENTAL
Intervention: Pharmacological approaches (disulfiram, acamprosate, naltrexone)
Number of subjects: 400000
Study: 15870437

Group type: EXPERIMENTAL
Intervention: Dose-dense ICE chemotherapy (4-week interval)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Standard ICE chemotherapy (2-week interval)
Number of subjects: 318
Study: 13678872

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg once daily
Number of subjects: 12218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12218
Study: 10202683

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium (IPM/CS)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Beta-lactam (ceftazidime or sulbactam/cefoperazone)
Number of subjects: 148
Study: 8694724

Group type: EXPERIMENTAL
Intervention: Topical 0.5% ketorolac tromethamine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Topical 0.1% diclofenac sodium
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both ketorolac and diclofenac
Number of subjects: 15
Study: 1723467

Group type: EXPERIMENTAL
Intervention: Nitrendipine, 20 mg b.i.d.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nitrendipine, 20 mg once daily
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 3
Study: 540459

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study: 31851556

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) in combination with intensive induction and consolidation therapy
Number of subjects: 588

Group type: COMPARATOR
Intervention: Standard arm (idarubicin, cytarabine, etoposide, and all-trans-retinoic acid without GO)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 588
Study: 31301329

Group type: EXPERIMENTAL
Intervention: BPKs washed with water and detergent after each use and further steam decontamination within a microwavable bag (Study group, N=21)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Washing, rinsing and drying only (Control group, N=26)
Number of subjects: 47
Study: 27549602

Group type: EXPERIMENTAL
Intervention: Web-based skin cancer prevention intervention
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control group (teen alcohol prevention website)
Number of subjects: 443
Study: 26727762

Group type: COMPARATOR
Intervention: HDM-SCIT
Number of subjects: 48

Group type: COMPARATOR
Intervention: HDM-SLIT
Number of subjects: 48
Study: 23677021

Group type: EXPERIMENTAL
Intervention: User-filled paper applicator
Number of subjects: 25

Group type: COMPARATOR
Intervention: Prefilled plastic applicator
Number of subjects: 25
Study: 21346613

Group type: EXPERIMENTAL
Intervention: Citalopram treatment (up to 12 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 0
Study: 19189775

Group type: EXPERIMENTAL
Intervention: Sleep group (N=26)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wake group (N=27)
Number of subjects: 53
Study: 17101560

Group type: EXPERIMENTAL
Intervention: CCK plasma levels measurement
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: DBI expression measurement
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CCK/DBI ratio measurement
Number of subjects: 44
Study: 14751955

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (15% FIO(2))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normobaric normoxia
Number of subjects: 8
Study: 11506099

Group type: EXPERIMENTAL
Intervention: Metaraminol infusion starting at 0.25 mg/min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ephedrine infusion starting at 5 mg/min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 9402565

Group type: EXPERIMENTAL
Intervention: Protonics knee brace at resistance level 9
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Protonics knee brace at resistance level 6
Number of subjects: 19

Group type: COMPARATOR
Intervention: Protonics knee brace at resistance levels 6 and 2 with flexion module
Number of subjects: 19
Study: 8430233

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2892895

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indenolol
Number of subjects: 20
Study: 28856661

Group type: EXPERIMENTAL
Intervention: Silk garments for the treatment of eczema
Number of subjects: 18